# The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

> **NCT01901341** · PHASE3 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 44 (actual)

## Conditions studied

- Opioid-Induced Constipation

## Interventions

- **DRUG:** CB-5945
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01901341
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07-02
- **Primary completion:** 2014-02-13
- **Final completion:** 2014-02-13
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Due to difficulties with enrollment, the study was terminated early.
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01901341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01901341, "The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01901341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*